Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a research study evaluating an investigational treatment.
General Anxiety Disorder
Age Range:
18 to 74
Gender:
Male and Female
Location:
West Chester, Pennsylvania
About the Study
This research study evaluates RE104, an investigational medication given as a single injection, designed to rapidly reduce anxiety symptoms and potentially provide sustained improvement after one dose.
Qualifications
You May Qualify If:
-Are 18 to 74 years of age
-Have moderate to severe anxiety symptoms
-Are willing and able to attend study visits and follow study procedures
-Have someone available to escort you home after the dosing visit
FEATURED STUDIES
General Anxiety Disorder
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a
COPD
Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a
MDD Study
Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating
Chronic Obstructive Pulmonary Disease (COPD)
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Post-Traumatic Stress Disorder (PTSD)
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Bronchiectasis
Individuals with bronchiectasis who experience frequent flare-ups or ongoing respiratory symptoms may qualify for a research study evaluating a home